InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Genenta Science S.p.A.

GNTA Clue Score33
Italy CIK 0001838716
$0.79 +10.58% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $0.79 −85.72% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 15 Dec 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2019Operating income−4.6Net income−4.6Fiscal year 2020Operating income−5.6Net income−5.6Fiscal year 2021Operating income−5.7Net income−5.5EPS, diluted−0.37Fiscal year 2022Operating income−11.0Net income−8.5EPS, diluted−0.47Fiscal year 2023Operating income−11.7Net income−11.6EPS, diluted−0.64Fiscal year 2024Operating income−9.8Net income−8.9EPS, diluted−0.49Fiscal year 2025Operating income−6.6Net income−6.5EPS, diluted−0.33
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating income −4.6 −5.6 −5.7 −11.0 −11.7 −9.8 −6.6
Net income −4.6 −5.6 −5.5 −8.5 −11.6 −8.9 −6.5
Growth
EPS, diluted n/a n/a −0.37 −0.47 −0.64 −0.49 −0.33
Growth

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2019Operating cash flow−2.5Fiscal year 2020Operating cash flow−6.0Capital expenditure−0.0Free cash flow−6.1Fiscal year 2021Operating cash flow−7.0Capital expenditure−0.0Free cash flow−7.0Fiscal year 2022Operating cash flow−7.4Capital expenditure−0.0Free cash flow−7.4Fiscal year 2023Operating cash flow−11.2Capital expenditure−0.0Free cash flow−11.2Fiscal year 2024Operating cash flow−6.2Capital expenditure−0.0Free cash flow−6.2Fiscal year 2025Operating cash flow−6.9Capital expenditure−0.0Free cash flow−6.9
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −2.5 −6.0 −7.0 −7.4 −11.2 −6.2 −6.9
Capital expenditure n/a −0.0 −0.0 −0.0 −0.0 −0.0 −0.0
Free cash flow n/a −6.1 −7.0 −7.4 −11.2 −6.2 −6.9
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2019Shareholders’ equity18.9Fiscal year 2020Cash15.5Shareholders’ equity15.2Fiscal year 2021Cash37.2Shareholders’ equity38.9Fiscal year 2022Cash29.8Shareholders’ equity31.1Fiscal year 2023Cash3.7Shareholders’ equity20.4Fiscal year 2024Cash4.6Shareholders’ equity12.5Fiscal year 2025Cash5.5Shareholders’ equity21.8
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash n/a 15.5 37.2 29.8 3.7 4.6 5.5
Shareholders’ equity 18.9 15.2 38.9 31.1 20.4 12.5 21.8

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
3.7 4.7 3.4 5.3 6.5 4.8 2.7
0.9 0.9 2.3 5.7 5.3 5.0 3.9
−4.6 −5.6 −5.7 −11.0 −11.7 −9.8 −6.6
Growth
−4.6 −5.6 −5.5 −8.5 −11.6 −8.9 −6.5
−4.6 −5.6 −5.5 −8.5 −11.6 −8.9 −6.5
Growth
Per share
n/a n/a −0.37 −0.47 −0.64 n/a n/a
n/a n/a −0.37 −0.47 −0.64 −0.49 −0.33
Growth
n/a n/a 15.1 18.2 18.2 18.3 19.7
n/a n/a 15.1 18.2 18.2 18.3 19.7
Growth +20.8% +0.0% +0.3% +7.9%

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 7 of 7 years on file.